Press Releases

Press Releases

  1. BTG Announces Positive Data from RENEW study of PneumRx® Coils

  2. BTG receives 510k clearance for LC Bead LUMI™

  3. BTG Announces FDA Approval of VISTOGARD® (Uridine Triacetate) as Antidote to Overdose and Early Onset, Severe, or Life-Threatening Toxicities from Chemotherapy Drugs 5-Fluorouracil (5-FU) or Capecitabine

  4. BTG plc: Interim Results 2015 - Replacement

  5. BTG plc: Interim Results 2015

  6. BTG and MIRADA Collaborate to Develop Dosimetry Software Solutions to Optimise Radioembolisation Therapy in Interventional Oncology

  7. BTG plc: close period update

  8. BTG announces positive safety and efficacy data in over 500 DC BeadM1 patients and compelling health economic data for TheraSphere

  9. BTG Announces FDA Acceptance of Wellstat Therapeutics’ New Drug Application for Uridine Triacetate as Antidote to Overexposure to Chemotherapy Drug 5-Fluorouracil (5-FU)

  10. BTG strides through Trekfest challenge for cancer charity

  11. BTG steps up to the Trekfest challenge for cancer charity

  12. Acute Pulmonary Embolism Trial (SEATTLE II) Published in the JACC: Cardiovascular Interventions

  13. Health Canada approves Varithena® (polidocanol injectable foam) for patients with varicose veins

  14. BTG plc: Annual General Meeting

  15. BTG plc: Annual Report and Accounts 2015

  16. First Patient in Singapore Treated with TheraSphere® Radioembolization Therapy

  17. BTG plc: Final Results

  18. REVOLENS study of PneumRx® endobronchial coils in severe emphysema meets primary endpoint

  19. BTG plc: close period update

  20. BTG begins sale of DC Bead® and Bead Block® directly to Physicians

  21. BTG plc launches a Level 1 ADR programme

  22. BTG plc updates revenue guidance and ceases publication of interim management statements

  23. Completion of the acquisition of PneumRx, Inc.